Rapid identification of enantioselective ketone reductions using targeted microbial libraries

A collection of about 300 microbes was surveyed for the ability to generate chiral secondary alcohols by enantioselective reduction of a series of alkyl aryl ketones. Microbial cultures demonstrating utility in reducing model ketones were arrayed in multi-well plates and used to rapidly identify specific organisms capable of producing chiral alcohols used as intermediates in the synthesis of several drug candidates. Approximately 60 cultures were shown to selectively reduce various ketones providing both the R and S enantiomers of the corresponding alcohols in 92–99% ee with yields up to 95% at 1–4 g/L. An alternative approach to chiral alcohols based on selective microbial oxidation of racemic alcohols is also reported. This study provides a useful reference for generating chiral alcohols by selective microbial bioconversion.

[1]  W. Hummel,et al.  Isolation and biochemical characterization of a new NADH oxidase from Lactobacillus brevis , 2004, Biotechnology Letters.

[2]  A. Medici,et al.  Kinetic resolution of racemic secondary alcohols via oxidation with Yarrowia lipolytica strains , 2000 .

[3]  J. Kreit,et al.  Substrate characterization of a NAD-dependent secondary alcohol dehydrogenase from Rhodococcus sp. GK1 (CIP 105335) , 2002 .

[4]  Michael Müller,et al.  Highly Enantioselective Preparation of Multifunctionalized Propargylic Building Blocks , 2002 .

[5]  C. Richard,et al.  Synthesis of Trimegestone: The First Industrial Application of Bakers' Yeast Mediated Reduction of a Ketone , 1997 .

[6]  Chi‐Huey Wong,et al.  Lactobacillus kefir alcohol dehydrogenase: a useful catalyst for synthesis , 1992 .

[7]  Karlheinz Drauz,et al.  Enzyme Catalysis in Organic Synthesis , 1995 .

[8]  T. Kusumi,et al.  High-field FT NMR application of Mosher's method. The absolute configurations of marine terpenoids , 1991 .

[9]  A. Straathof,et al.  Reduction of ethyl 3-oxobutanoate using non-growing baker’s yeast in a continuously operated reactor with cell retention , 2002 .

[10]  J. Lachowicz,et al.  Enhancement of pharmacokinetic properties and in vivo efficacy of benzylidene ketal M(2) muscarinic receptor antagonists via benzamide modification. , 2002, Bioorganic & Medicinal Chemistry Letters.

[11]  B. Neustadt,et al.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides. , 2003, Bioorganic & medicinal chemistry letters.

[12]  R. Lanciotti,et al.  Anti-Prelog microbial reduction of prochiral carbonyl compounds , 1996 .

[13]  H. Motamedi,et al.  Purification, characterization and immobilization of an NADPH-dependent enzyme involved in the chiral specific reduction of the keto ester M, an intermediate in the synthesis of an anti-asthma drug, Montelukast, from Microbacterium campoquemadoensis (MB5614) , 1998, Applied Microbiology and Biotechnology.

[14]  Ramesh N. Patel,et al.  Microbial synthesis of (2R,3S)-(-)-N-benzoyl-3-phenyl isoserine ethyl ester-a taxol side-chain synthon , 1993 .

[15]  A. Liese,et al.  New Continuous Production Process for Enantiopure (2R,5R)-Hexanediol , 2002 .

[16]  A. Medici,et al.  Homochiral (R)- and (S)-1-heteroaryl- and 1-aryl-2-propanols via microbial redox , 1998 .

[17]  D. Schomburg,et al.  The crystal structure of R-specific alcohol dehydrogenase from Lactobacillus brevis suggests the structural basis of its metal dependency. , 2003, Journal of molecular biology.

[18]  J. Murrell,et al.  Purification and characterization of a NAD+-dependent secondary alcohol dehydrogenase from propane-grown Rhodococcus rhodochrous PNKb1 , 2004, Archives of Microbiology.

[19]  K. Drauz,et al.  Towards a Large‐Scale Asymmetric Reduction Process with Isolated Enzymes: Expression of an (S)‐Alcohol Dehydrogenase in E. coli and Studies on the Synthetic Potential of this Biocatalyst , 2003 .

[20]  C. Moitzi,et al.  Biocatalytic asymmetric hydrogen transfer. , 2002, Angewandte Chemie.

[21]  Ramesh N. Patel,et al.  Biocatalytic synthesis of some chiral drug intermediates by oxidoreductases , 1997 .

[22]  V. Prelog.  Specification of the stereospecificity of some oxido-reductases by diamond lattice sections , 1964 .

[23]  Cheryl A. Grice,et al.  Synthesis and structure-activity relationships of oxime neurokinin antagonists: discovery of potent arylamides. , 2002, Bioorganic & medicinal chemistry letters.

[24]  P. Adlercreutz.  Novel biocatalyst for the asymmetric reduction of ketones: Permeabilized cells of Gluconobacter oxydans , 1991 .

[25]  G. Sheldrake,et al.  Enantiocomplementary preparation of (S)- and (R)-1-pyridylalkanols via ketone reduction and alkane hydroxylation using whole cells of Pseudomonas putida UV4 , 2002 .

[26]  Ramesh N. Patel,et al.  Microbial/enzymatic synthesis of chiral drug intermediates. , 2000, Advances in applied microbiology.

[27]  B. Neustadt,et al.  Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. , 2001, Journal of medicinal chemistry.

[28]  J. Lachowicz,et al.  Correlation of neurokinin (NK) 1 receptor occupancy in gerbil striatum with behavioral effects of NK1 antagonists. , 2002, The Journal of pharmacology and experimental therapeutics.

[29]  Ramesh N. Patel,et al.  Enantioselective microbial reduction of 2-oxo-2-(1′,2′,3′,4′-tetrahydro-1′,1′,4′,4′-tetramethyl-6′-naphthalenyl)acetic acid and its ethyl ester , 2002 .

[30]  W. Kroutil,et al.  Biocatalytic asymmetric hydrogen transfer employing Rhodococcus ruber DSM 44541. , 2003, The Journal of organic chemistry.

[31]  Ramesh N. Patel.  Microbial/enzymatic synthesis of chiral intermediates for pharmaceuticals , 2002 .

[32]  W. Greenlee,et al.  Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity. , 2002, Journal of medicinal chemistry.

[33]  B. Ludwig,et al.  A Long-Chain Secondary Alcohol Dehydrogenase from Rhodococcus erythropolis ATCC 4277 , 1995, Applied and environmental microbiology.

[34]  K. Kersters,et al.  [64] Primary and secondary alcohol dehydrogenases from Gluconobacter , 1966 .

[35]  B. Pugin,et al.  Selective Hydrogenation for Fine Chemicals: Recent Trends and New Developments , 2003 .

[36]  K. Drauz,et al.  Practical asymmetric enzymatic reduction through discovery of a dehydrogenase-compatible biphasic reaction media. , 2003, Organic letters.

[37]  R. Holt.  Microbial asymmetric reduction in the synthesis of a drug intermediate , 1996 .

[38]  M. Chartrain,et al.  Asymmetric bioreductions: application to the synthesis of pharmaceuticals , 2001 .